top of page

The chief medical officer of Astellas previews ASCO and talks about new modalities and targets the company has been working on

  • May 30, 2024
  • 1 min read

Tadaaki Taniguchi covers some of the work Astellas is doing with modalities like antibody-drug conjugates, T-cell engagers, and protein degradation, and targets such as Claudin 18.2.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page